

## Important notice

• This document contains statements about Mercia Asset Management PLC that are or may be forward-looking statements. Forward-looking statements include statements relating to (i) future revenues, expenses, earnings, financial condition and future prospects; and (ii) business and management strategies and the expansion and growth of Mercia Asset Management

PLC's operations.

• These forward-looking statements are not guarantees of future performance. They have not been reviewed by the auditors or advisers of Mercia Asset Management PLC. They involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements to be materially different from any results, performance or achievements expressed or implied by such statements. They are based on numerous assumptions regarding the present and future business strategies and the future operating environment. All subsequent oral or written forward-looking statements attributable to Mercia Asset Management PLC or any of its shareholders or any persons acting on its behalf are expressly qualified in their entirety by this cautionary statement. All forward-looking statements included in this document speak only as of the date they were made and are based on information then available to Mercia Asset Management PLC. Investors should not place undue reliance on such forward-looking statements, and Mercia Asset Management PLC does not undertake any obligation to update publicly or revise any forward-looking statements.

• No representation or warranty, express or implied, is given regarding the accuracy of the information or opinions contained in this document and no liability is accepted by Mercia Asset Management PLC or any of its Directors, members, officers,

employees, agents or advisers for any such information or opinions.

• This information is being supplied to you for information purposes only and not for any other purpose. This document and the information contained in it does not constitute or form any part of an offer of, or invitation or inducement to apply for, securities.

• The distribution of this document in jurisdictions other than the United Kingdom may be restricted by law and persons into whose possession this document comes should inform themselves about and observe any such restrictions. Any failure to comply with these restrictions may constitute a violation of laws of any such other jurisdiction.



## An entrepreneurial leadership team with a track record of value realisation



Dr Mark Payton
Chief Executive Officer

Over 20 years' experience in tech. commercialisation and investing

PhD in Life Sciences

Co-founder of Mercia





Martin Glanfield Chief Financial Officer

Over 20 years' CFO experience of multiple listed and PE-backed technology-led businesses

Former CFO of Forward Group PLC

KPMG trained chartered accountant

Oversees debt team





Julian Viggars
Chief Investment Officer

Over 20 years' venture capital experience including Blue Prism IPO

Oversees the Group's equity investment activity

Chartered accountant





# Strong model delivering capital growth and yield



- Strong liquidity across the Group c.£297m funds and balance sheet
- Long dated managed funds, no redemptions
- Well funded portfolios, with low capital needs
- Strong commercial progress by the diversified direct portfolio
- Limited public markets exposure in the direct portfolio





# FY22 – Key results for the Group

#### **OPERATING**

31 March 2022:	c.£959m Group AuM	c.£124m Capital deployed	c.£155m Cash realised	c.£297m Total liquidity
31 March 2021:	c.£940m	c.£94m	c.£103m	c.£314m

#### **FINANCIALS**

31 March 2022:	£20.6m Group revenue*	£61.3m Unrestricted cash**	£27.4m Profit before taxation	45.6p NAV/share	<b>0.5p</b> Proposed final dividend Full year dividend of 0.8p
31 March 2021:	£19.2m*	£54.7m**	£34.0m	40.0p	<b>0.3p</b> Final dividend Full year dividend of 0.4p




<sup>\*</sup> Excluding performance fees
\*\* Including short-term liquidity investments

## The model - a debt-free group delivering

- Complimentary asset classes
- Recurring predictable fee income
- Growing profitability and operating cash inflow
- Scalable platform and systems to facilitate accelerated growth


#### Balance sheet returns



- Strong focus and discipline
- Invests in emerging funds' portfolio companies, selectively into managed funds and complimentary M&A to scale AuM
- Fully aligned



# Growing UK specialist asset manager



AuM	c.£36m	c.£959m
Unrestricted Group cash*	-	£61.3m
Debt	-	-
PBT	-	£27.4m
People	7	120
Offices	1	8

<sup>\*</sup> Including short-term liquidity investments



# Tailwinds for growth

## Scalable distribution:

- i. Retail investors (via EIS and VCT)
- ii. Public sector, via British Business Bank
- iii. Institutional capital (regional pension funds)

	Drivers for growth	Growing addressable opportunity
Retail capital (EIS / VCT)	Top-four manager in both classes	EIS: £1.6bn (2021) VCT: £1.1bn (2022)
British Business Bank / others	Currently manage c.40% of regional BBB funds. Next generation funds due FY 2023-24	£1.6bn committed in 2021 spending review to next generation regional funds
Institutional capital	Through PE and debt	Strong track record for further growth



## Strong M&A track record

#### What we look for:

- Value driver analysis
- Strong cultural fit
- Earnings enhancing
- Domestic market expansion via new FuM
- Similar fee structures
- vi. Strong fit with investment model and internal capabilities / systems





2016

Acquired entire group (£11m): - c.£200m FuM

- 7.9x PBT


2019

Acquired 3 VCT fund management contracts plus team (£25m):

- c.£270m FuM
- 6.3x PBT



FY22 – FY24 Our three-year strategic goals



Achieve average pre-tax profits of £20million per annum over the next three years

**Grow NAV/share** 

Grow AuM by an average of 20% per annum over the same three-year period

Grow dividend

	PBT	AuM
FY22:	£27.4m	£959m
FY23:	-	-
FY24:	-	-
Three-year cumulative target:	c.£60m	c.£1.5bn





# FY22 – Key results for the Group


#### **HEADLINE FINANCIALS**

31 March 2022:	£20.6m Group revenue*	£8.4m Adjusted operating profit	£27.4m Profit before taxation	£61.3m Unrestricted cash**	45.6p NAV/share
31 March 2021:	£19.2m*	£3.3m	£34.0m	£54.7m**	40.0p



Excluding performance feesIncluding short-term liquidity investments

# Resilience of total revenue with AuM growth



\*Excludes performance, fund raising or other fees



# Consolidated statement of comprehensive income For the year ended 31 March 2022

	V II	V 1 1
	Year ended	Year ended
	31 March	31 March
	2022	2021
	£,000	£'000
Revenue	23,183	23,410
Administrative expenses	(17,857)	(16,554)
Realised gain on sale of direct investment	9,878	20,251
Fair value movements in direct investments	11,385	10,088
Share-based payments charge	(1,109)	(543)
Amortisation of intangible assets	(2,033)	(2,317)
Movement in fair value of deferred consideration	(522)	(365)
Operating profit	22,925	33,970
Finance income	4,452	68
Finance expense	(15)	(20)
Profit before taxation	27,362	34,018
Taxation	(1,262)	440
Profit and total comprehensive income for the year	26,100	34,458
Basic earnings per Ordinary share (pence)	5.93	7.83
Diluted earnings per Ordinary share (pence)	5.82	7.83

- Realised gain on the sale of Faradion
- Fair value movement +c.13% vs March 2021



# Consolidated statement of financial position

As at 31 March 2022	As at	As at	
	31 March	31 March	
	2022	2021	
	£,000	£'000	
Goodwill and intangible assets	32,355	34,388	Direct portfolio:
Property, plant and equipment and right-of use assets	530	563	<ul> <li>Net capital deployed £18.4m</li> </ul>
Investments	119,558	96,220	• FVM +£11.4m
Total non-current assets	152,443	131,171	
Trade and other receivables	1,074	4,060	<ul> <li>+c.24% vs. March 2021</li> </ul>
Restricted cash	_	2,484	
Cash, cash equivalents and short-term liquidity investments	61,284	54,725	Significant liquidity of £61.3m
Total current assets	62,358	61,269	with no debt '
Total assets	214,801	192,440	
Trade, other payables and lease liabilities	(7,120)	(8,249)	
Deferred consideration	(2,869)	(1,578)	
Total current liabilities	(9,989)	(9,827)	
Lease liabilities	(295)	(351)	
Deferred consideration	_	(2,869)	
Deferred taxation	(3,928)	(3,372)	
Total non-current liabilities	(4,223)	(6,592)	
Total liabilities	(14,212)	(16,419)	
Net assets	200,589	176,021	NAV per share 45.6p +c.14%
Equity		_	vs. March 2021
Issued share capital	4	4	
Share premium	81,644	81,644	
Other distributable reserve	66,919	69,560	FY21 final dividend 0.3p/share
Retained earnings	48,505	22,405	FY22 interim dividend 0.3p/share
Share-based payments reserve	3,517	2,408	1 122 interim dividend 0.0p/share
Total equity	200,589	176,021	



# Consolidated statement of cash flows

For the year ended 31 March 2022

	Year ended Y	ear ended	
	31 March	31 March	
	2022	2021	
	£,000	£,000	
Net cash generated from operating activities	9,150	5,611	<ul> <li>Strong operating cash inflow</li> </ul>
Sale of direct investments	16,309	36,987	
Purchase of direct investments	(19,884)	(15,647)	N + C10 4   1   1   1
Investee company loan repayments	1,500	250	• Net £18.4m capital deployed
Investee company loan redemption premiums and interest received	4,438	50	
Net cash generated from direct investment activities	2,363	21,640	
Interested received from cash, cash equivalents and STLI	14	18	
Purchase of property, plant and equipment	(76)	(52)	
Purchase of fund management contracts	(2,100)	(2,100)	
(Increase)/decrease in short-term liquidity investments	(5,001)	5,981	
Net cash (used in)/generated from other investing activities	(7,163)	3,847	
Dividends paid	(2,641)	(440)	
Interest paid	(15)	(20)	
Payment of lease liabilities	(136)	(118)	
Net cash used in financing activities	(2,792)	(578)	
Net increase in cash and cash equivalents	1,558	30,520	
Cash and cash equivalents at the beginning of the year	54,491	23,971	
Cash and cash equivalents at the end of the year	56,049	54,491	<ul> <li>+£5.3m short-term liquidity investments</li> </ul>



## Mercia share register: 69% free float (2021: 69%)

- Board, management and employees (c.17%)
- Invesco (c.14%)
- Retail (c.10%)
- Ruffer (c.7%)
- Chelverton Asset Management (c.4%)
- BMO Global Asset Management (c.4%)
- The Hargreaves No.11 Settlement (c.3%)
- NFU Mutual (c.3%)
- BlackRock (c.3%)
- Librae Holdings (c.3%)

#### Others of note:

- Ninety One
- Hargreave Hale
- Liontrust
- West Yorkshire Pension Fund
- Unicorn
- Fidelity





## FY22 - AuM movements

Asset class	AuM 1 April 2021 £'m	Private investor inflows £'m	Public sector inflows £'m	Performance £'m	Distributions £'m	AuM 31 March 2022 £'m	Post year- end inflows £'m
Venture	600	22	20	30	(80)	592	45
Private equity	54	-	-	(2)	(4)	48	-
Debt	110	-	11	-	(3)	118	-
Total FuM	764	22	31	28	(87)	758	45
Proprietary capital	176	-	-	28	(3)	201	-
Total AuM	940	22	31	56	(90)	959	45

- Three EIS funds raised in the year and additional fund allocations by BBB
- Venture, debt and propriety capital distributions to investors
- Performance driven by EIS, legacy venture and direct investment portfolio fair value increases



# FY22 - Key investment figures for the Group

#### **INVESTMENT**

31 March 2022:	ch 2022: 2,604 c.£124m Investment requests Capital deployed		148 Businesses invested	95 New to portfolio
31 March 2021:	2,818	c.£94m	173	76


#### **PERFORMANCE**

31 March 202	c.£155m Investment returns	3.1x Investment multiple	13 Trade sales	3 IPOs	17 Other full or partial exit events
31 March 2021	c.£103m	5.7x	6	1	4



## £155m of realisations for FY22


## **Equity realisations**



Venture (managed funds)Private Equity (managed funds)









#### Faradion – 2011 to 2022 realisation



**Ashwin Kumaraswamy Investment Director** 

Founded by Dr Jerry Barker and Dr Chris Wright, with seed investment from Mercia

2011

First direct investment from Mercia was made in 2017

2017

Sold to Reliance New Energy Solar in January 2022

2022

Mercia's managed funds have held equity in the company since 2011

2019 James Quinn

joins as CEO

Total cash proceeds of £19.4m resulted in a realised gain of £9.9m; a 4.4x return on Mercia's direct investment cost of £4.4m.



# Direct investment portfolio as at 31 March 2022

	Year of first direct investment	Investment value As at 1 April 2021 £'000	Net cash invested Year to 31 March 2022 £'000	Investment realisations Year to 31 March 2022 £'000	Realised gains Year to 31 March 2022 £'000	Fair value movement Year to 31 March 2022 £'000	Investment value As at 31 March 2022 £'000	Percentage held As at 31 March 2022 %
nDreams Ltd	2014	17,726	1,301	-	-	6,734	25,761	33.2
Intechnica Group Ltd	2017	9,996	1,531	-	-	2,884	14,411	24.1
Voxpopme Ltd	2018	8,845	1,500	-	-	166	10,511	17.6
Impression Technologies Ltd	2015	8,622	1,750	-	_	-	10,372	67.3
Medherant Ltd	2016	8,105	534	-	-	350	8,989	33.1
Warwick Acoustics Ltd	2014	4,255	1,039	-	-	1,012	6,306	40.0
Ton UK Ltd t/a Intelligent Positioning	2015	4,913	660	-	-	501	6,074	29.9
VirtTrade Ltd t/a Avid Games	2015	2,812	1,096	-	-	1,479	5,387	40.6
Locate Bio Ltd	2018	3,006	1,664	-	-	188	4,858	18.1
Invincibles Studio Ltd (formerly Soccer Manager Ltd)	2015	3,553	-	-	-	1,047	4,600	39.0
Eyoto Group Ltd	2017	1,813	1,147	-	-	-	2,960	15.7
W2 Global Data Solutions Ltd	2018	2,300	200	-	-	-	2,500	16.3
Sense Biodetection Ltd	2020	945	909	-	-	625	2,479	1.6
sureCore Ltd	2016	2,417	-	-	-	-	2,417	22.0
Edge Case Games Ltd	2015	2,300	-	-	-	-	2,300	18.7
PsiOxus Therapeutics Ltd	2015	2,407	-	-	-	(627)	1,780	1.4
Forensic Analytics Ltd	2021	-	1,750	-	-	-	1,750	8.9
MyHealthChecked plc	2016	4,488	-	-	-	(2,856)	1,632	13.1
MIP Discovery Ltd (formerly MIP Diagnostics Ltd)	2020	302	1,147	-	-	-	1,449	10.2
Pimberly Ltd	2021	-	1,375	-	-	-	1,375	5.6
Faradion Ltd	2017	5,693	738	(16,309)	9,878	-	_	_
Other direct investments	n/a	1,722	43	-	-	(118)	1,647	n/a
Total		96,220	18,384	(16,309)	9,878	11,385	119,558	n/a

# More to come from proprietary investments

40.0%

WARWICK


ACOUSTICS

South Back Control



15.7%

EYOTO





40.6%



## Shadow portfolio, ones to watch





#### NOVAPANGAEA

Processes that enable the conversion of woody and agricultural plant residues into high-value sustainable biocarbons, biopolymers, biochemicals and advanced biofuels.



Implant systems that achieve and maintain superior spinal alignment for improved clinical outcomes.



#### TRIBOSONICS

Embedded sensing technology that transforms components into intelligent and efficient systems.



# **⊌**∩ıphy

A seamless smart surface that can be formed into any shape, whilst feeling and working exactly as you'd expect.



Delivers artificial intelligent solutions, that have the ability to perceive, understand and continuously learn.



The Dxcover Platform has been developed to enable earlier detection of cancer.



## Responsible investor, responsible employer

- Mercia is proof that Responsible Investment works
- Dedicated team (which includes Mercia's CEO) representing all parts of the Group, led by Jill Williams
- First Knowledge-intensive Impact EIS Fund launched (with more to come)
- 120 employees in 8 regional offices, with
   19 university partnerships
- c.39% of staff, c.20% of investment team and two of Mercia's NEDs are women

# Making an impact













# **Summary and outlook**







# Proactive regional deal origination

	National EIS/VCT	Regional Venture	Private Equity	Debt	Proprietary capital
Investment criteria:	Early stage, series A, up to £5m	Early stage, up to £2m	Profitable, up to £5m	Profitable, up to £1m	Series A, up to £10m
Total portfolio size:	131	119	10	171	23
Investments made this period:	£58m	£26m	£9m	£13m	£18m
New to portfolio:	22	21	2	48	2
AuM:	£400m	£192m	£48m	£118m	£201m
Cash:	£121m	£41m	£15m	£59m	£61m*

<sup>\*</sup> Including short-term liquidity investments



# Top 10 holdings, by value (1-5)

	□Dreams	intachnica	*** Voxpopme*	Impression	MEDHERANT
Investment value	£25.8m	£14.4m	£10.5m	£10.4m	£9.0m
% direct holding (excludes FuM)	33.2%	24.1%	17.6%	67.3%	33.1%
Initial year of investment	2014	2017	2018	2015	2016
Description	VR developer	E-commerce/ web security	Video analytics	Aluminum pressing	Patch delivery
Board representation	Yes	Yes	Yes	Yes	Yes
Key metrics	Revenue, partnerships	Revenue, ARR	Revenue, ARR	Licences, partnerships	Regulatory, clinical, partnerships
Highlights FY22	£20.1m investment, growth	Separation of Netacea, growth	30% growth	Progress in battery boxes/ recycled aluminium	3 partners+ internal pipeline
Valuation change	1	1		=	1



# Top 10 holdings, by value (6-10)


	WARWICK ACOUSTICS		EVERYTHING	a locate	INVINCIBLES STUDIO	
Investment value	£6.3m	£6.lm	£5.4m	£4.9m	£4.6m	
% direct holding (excludes FuM)	40.0%	29.9%	40.6%	18.1%	39.0%	
Initial year of investment	2014	2015	2015	2018	2015	
Description	Flat speaker tech	Business intelligence	Mobile digital trading cards	Orthobiologics	Mobile soccer management game	
Board representation	Yes	Yes	No	Yes	Yes	
Key metrics	Licences, partnerships	Revenue, ARR	Revenue, partnerships	Revenue, partnerships	Revenue, partnerships	
Highlights FY22	Market awareness/ OEM progress	Return to growth	Significant game revenue growth	Clinical progress	Authenticity with licenses, growth	
Valuation change	1	1	1	1		



## Valuation methodology

- Follow IPEVCV Guidelines
- Over half of the portfolio value based on the price of last investment round
- Calibration of valuation approaches
- Some use of DCF due to valuation guidelines
- Minimal exposure to volatile public market conditions
- Still adopt a 'hand-on-heart' final review

# Direct investment portfolio by valuation methodology






#### **Investment focus**

- Direct investments balanced across key sectors
- Current focus areas include digital health, business efficiency, energy transition and enabling technology
- Exciting progress made by all sectors

#### Direct investment portfolio by sector









lan Metcalfe Chair



Diane Seymour-Williams
SID



Ray Chamberlain



**Dr Jonathan Pell** 



**Caroline Plumb OBE** 

